ライフサイエンスコーパス: apathy

1 diminished sustained attention, fatigue, and apathy.

2 sion was only 2.62% compared with 14.60% for apathy.

3 observed here might be a useful correlate of apathy.

4 enia patients with high versus low levels of apathy.

5 isorders showing frontal lobe involvement in apathy.

6 ported the role of the anterior cingulate in apathy.

7 nsions of affective flattening and avolition-apathy.

8 e closely associated with the development of apathy.

9 .004) and were unchanged in patients without apathy.

10 posterior cortical areas could contribute to apathy.

11 mited understanding of mechanisms underlying apathy.

12 ased initiation apathy and reduced emotional apathy.

13 e on medication, and assessed in relation to apathy.

14 of which were dystonia, speech disorder, and apathy.

15 behavioural dysfunction with high levels of apathy.

16 thway in cognitively intact PD patients with apathy.

17 inically significant) with depression (20%), apathy (15%), and irritability (15%) being most common.

18 Apathy (27%), depression (24%), and agitation/aggression

19 ementia, the most frequent disturbances were apathy (36%), depression (32%), and agitation/aggression

20 Depression (56% versus 17%, P = 0.0003), apathy (40% versus 4%, P < 0.0001), disinhibition (16% v

21 parkinsonism (95.2% of patients), depression/apathy (71.4%), respiratory symptoms (66.7%) and weight

22 showed a greater mean reduction in avolition-apathy (adjusted mean [SE], 1.66 [0.31] vs 2.81 [0.34],

23 Four DLB patients with apathy and 4 DLB patients without apathy were identified

24 ToM deficit also displayed higher levels of apathy and a naming deficit.

25 ate psychiatric symptoms such as depression, apathy and anxiety are risk factors for or prodromal sym

26 functioning and psychiatric symptoms (e.g., apathy and avolition), but not psychotic symptoms (e.g.,

27 ng correlation was found between measures of apathy and both attenuated P3 amplitude and viewing dura

28 Moreover, effective treatments for apathy and cognitive decline do not currently exist.

29 had lower performance IQ scores than the low apathy and comparison groups.

30 This study investigated whether apathy and depression can be distinguished in small vess

31 studied in order to interpret the degree of apathy and depression found within the small vessel dise

32 symptoms, e.g. gait and balance impairment, apathy and depression in Alzheimer's disease patients su

33 ession and cognitive impairment; and (ii) if apathy and depression make independent contributions to

34 n of behavioral profiles, differentiation of apathy and depression, characterization of risk factors

35 regions of white matter were associated with apathy and depression, controlling for age, gender and c

36 sel disease is associated with high rates of apathy and depression, thought to be caused by a disrupt

37 re not blood loss and infection but, rather, apathy and disdain toward women.

38 egative symptoms (such as social withdrawal, apathy and emotional blunting) and other psychopathologi

39 This accommodates the commonalities of apathy and impulsivity across disorders and reveals thei

40 The ability to measure the components of apathy and impulsivity and their associated neural corre

41 Apathy and impulsivity are common and disabling conseque

42 Measures of apathy and impulsivity frequently loaded onto the same c

43 o determine the neurocognitive components of apathy and impulsivity in frontotemporal lobar degenerat

44 We derived dimensions of apathy and impulsivity using principal component analysi

45 The frequency and characteristics of apathy and impulsivity were determined by neuropsycholog

46 Apathy and impulsivity were present across diagnostic gr

47 obar degeneration provides new insights into apathy and impulsivity, and the need for a joint therape

48 mutation presented a contrasting picture of apathy and inertia.

49 for subgroups (r = 0.49, p = 0.04), whereas apathy and left anterior cingulate NFTs showed a signifi

50 esent in some patients with ALS, manifest as apathy and loss of awareness.

51 f medication effects on clinical measures of apathy and motor dysfunction.

52 onsignificant trend toward less worsening in apathy and no significant between-group differences in a

53 nsitivity may be a contributory mechanism to apathy and provide potential new clinical measures for i

54 aggression, obsessive/compulsive behaviours, apathy and psychosis.

55 y a specific profile of increased initiation apathy and reduced emotional apathy.

56 pathway complement consumption and provoked apathy and reduced nociceptive responses in rats.

57 nxiety or depression, cognitive decline, and apathy), and additional features (fatigue, insomnia, ano

58 t developed increasing reasoning difficulty, apathy, and disinhibition.

59 with poor quality of life, disease severity, apathy, and exposure to antimuscarinics.

60 amily, knowledge, information, media, grief, apathy, and fear.

61 manifest disproportionate disinhibition and apathy, and may exhibit compulsions.

62 demonstrated increased rates of depression, apathy, and other behavioural symptoms in the mildly sym

63 e mania, bipolar disorder, anxiety disorder, apathy, and pathological crying.

64 horizontal and vertical saccades, dysphagia, apathy, and progressive cognitive decline, which led to

65 itive symptoms, such as anxiety, depression, apathy, and psychosis, that impair daily living.

66 t non-cognitive features include depression, apathy, and psychosis.

67 sease course), mood (especially, depression, apathy, and suicidality), personality and behavior (espe

68 ease focusing on symptoms of depressed mood, apathy, anhedonia, or anergia.

69 The primary outcome for apathy (Apathy Evaluation Scale-Clinician) and secondary

70 ral symptoms of sickness such as fatigue and apathy are debilitating and can prevent recuperation.

71 Factor analyses showed that empathy and apathy are distinct constructs, but that affective empat

72 Mechanisms underlying apathy are poorly understood and clinically we lack robu

73 radykinesia) and motivational deficit (i.e., apathy) are hallmarks of Parkinson's disease (PD).

74 t is, 'negativity bias' (negative valence), 'apathy' (arousal) and 'emotional dysregulation' (cogniti

75 variable measurement scales and the focus on apathy as a unitary concept.

76 n carriers was behavioural variant FTLD with apathy as the dominant feature.

77 s of HD in this European HD population, with apathy as the most frequent symptom.

78 Apathy, as a syndrome, has recently been associated with

79 nergisation'-the loss of which is central in apathy-as a core executive function.

80 ree patients, memory loss was accompanied by apathy but no other behavioural changes.

81 in small vessel disease are associated with apathy but not directly with depressive symptoms.

82 t both drugs improved cognitive function and apathy, but had a stronger effect when used in combinati

83 These results suggest that apathy, but not depression, in small vessel disease is r

84 dication might be an effective treatment for apathy by increasing reward sensitivity, independent of

85 can be driven by goals, hence accounting for apathy cases in clinics.

86 as significantly reduced in PD patients with apathy compared with nonapathetic patients and healthy c

87 ips between median fractional anisotropy and apathy, depression and cognitive impairment; and (ii) if

88 and completed cognitive testing, measures of apathy, depression, quality of life and diffusion tensor

89 urs examined, 4 correlated with tissue loss: apathy, disinhibition, eating disorders and aberrant mot

90 studies, we revise a neurocircuitry model of apathy divided along three subcomponents (cognition/plan

91 asked to complete the DAS, the standardised Apathy Evaluation Scale, and the Geriatric Depression Sc

92 The primary outcome for apathy (Apathy Evaluation Scale-Clinician) and secondary outcome

93 o measure 3 neurologically based subtypes of apathy: Executive, Emotional and Initiation.

94 The high apathy group had lower performance IQ scores than the lo

95 The high apathy group scored lower than comparison subjects on ra

96 Only the high apathy group showed significantly reduced bilateral fron

97 Apathy has profound consequences, such as functional imp

98 Levels of apathy have been consistently shown to correlate with th

99 ation (hazard ratio=3.06, 95% CI=1.89-4.93), apathy (hazard ratio=2.26, 95% CI=1.49-3.41), anxiety (h

100 Methylphenidate improved apathy in a group of community-dwelling veterans with mi

101 ral symptom by examining the substructure of apathy in ALS and to determine the reliability and valid

102 Apathy in ALS is characterised by a specific profile of

103 asure for the assessment of multidimensional apathy in ALS.

104 s to study the effects of methylphenidate on apathy in Alzheimer's disease.

105 We reviewed all neuroimaging studies of apathy in frontotemporal dementia (FTD) attempting to re

106 Apathy in FTD is most robustly associated with atrophy,

107 low the progression of cognitive decline and apathy in neurological conditions where sleep is disorde

108 vation and reward sensitivity in relation to apathy in patients with Parkinson's disease.

109 Cognitive decline and apathy in R6/2 mice can be improved with sleeping drugs,

110 e trend was driven by changes in measures of apathy independent of dementia severity.

111 er, Mini-Mental State Examination score, and apathy/indifference, did not affect the rate of function

112 ally discriminating features (disinhibition, apathy/inertia, loss of sympathy/empathy, perseverative/

113 e to modify the bvFTD diagnostic criteria of apathy/inertia.

114 Apathy is a common behavioral problem in Alzheimer's dis

115 Apathy is a common negative symptom in schizophrenia.

116 Apathy is a common syndrome observed in many neurologica

117 Apathy is a debilitating and under-recognized condition

118 Apathy is a prominent symptom of amyotrophic lateral scl

119 Apathy is a symptom shared among many neurological and p

120 Apathy is one of the core features of behavioural varian

121 Apathy is one of the most common and debilitating nonmot

122 Schizophrenia patients with low apathy levels (N=18) and high apathy levels (N=20) and 1

123 ients with low apathy levels (N=18) and high apathy levels (N=20) and 12 healthy comparison subjects

124 bitofrontal cortex in AD, whereas increasing apathy may relate to greater NFT burden in the anterior

125 res for improved diagnosis and monitoring of apathy.media-1vid110.1093/brain/aww188_video_abstractaww

126 nistered self-report measures of empathy and apathy-motivation to a large sample of healthy people (n

127 Delusion, hallucination, agitation, anxiety, apathy, motor-disturbances, night-time behavior and eati

128 ese processes is likely to contribute to the apathy observed in patients after injury to the frontal

129 Moderate to severe apathy occurred in 28.1% of the participants, whereas mo

130 The unacceptable apathy of governments and funders of global health must

131 ential impact of syndromes such as mania and apathy on rehabilitation efforts or pathological crying

132 s, patients showed a significant increase in apathy on the Initiation subscale, and were significantl

133 area including (i) the assessment of either apathy or impulsivity alone, despite their frequent co-e

134 nguishing features between the 2 groups were apathy (OR, 4.53; 95% confidence interval [CI], 3.11-6.6

135 es were significantly lower in patients with apathy (P = 0.004) and were unchanged in patients withou

136 ndary outcomes included measures of anxiety, apathy, quality of life, and cognition.

137 al equation modelling results indicated both apathy (r = -0.23, P </= 0.001) and depression (r = -0.4

138 anisotropy was significantly associated with apathy (r = -0.38, P </= 0.001), but not depression (r =

139 Apathy was indexed by Lille Apathy Rating Scale (LARS) scores.

140 imulation measured by the Person-Environment Apathy Rating-Environment subscale (stimulation clarity,

141 Among psychiatric indicators, apathy ratings specifically showed significant increases

142 Apathy, REM sleep behaviour disorder, anosmia, hypersali

143 The new Dimensional Apathy Scale (DAS) has been specifically designed for pa

144 y modulation by incentives was predictive of apathy severity, and independent of motor impairment and

145 he Total Functional Capacity score, but with apathy showing the strongest inverse association.

146 ymptoms that occur in PD such as depression, apathy, sleep disorders (including rapid-eye movement sl

147 oup had significantly greater improvement in apathy than the placebo group at 4 weeks, 8 weeks, and 1

148 ontributes to continued misunderstanding and apathy toward fulfilling the regulatory and ethically ob

149 I scores (4.67 [3.21-6.78]), the presence of apathy (UPDRS item 4) (1.94 [1.33-2.82]), a higher levod

150 Apathy was associated with GM density loss in the anteri

151 On voxel-based analysis, apathy was associated with widespread reduction in white

152 In addition, apathy was independently associated with tissue loss in

153 Apathy was indexed by Lille Apathy Rating Scale (LARS) s

154 Apathy was the key neuropsychiatric symptom occurring mo

155 Apathy was the most common behavioural feature, while hy

156 In contrast, when controlling for apathy, we found no significant relationship between our

157 y clinical signs of parkinsonism, depression/apathy, weight loss, respiratory symptoms, mutations in

158 chsler tests, and cognitive fluctuations and apathy were also assessed.

159 Depressed mood, anhedonia, anergia, and apathy were assessed at baseline using a structured beha

160 presenting clinically meaningful symptoms of apathy were compared with nonapathetic PD patients and h

161 ients with apathy and 4 DLB patients without apathy were identified.

162 stroke are depression, anxiety, fatigue, and apathy, which each occur in at least 30% of patients and